ArticleInternational journal of molecular sciences2021

YES1 as a Therapeutic Target for HER2-Positive Breast Cancer after Trastuzumab and Trastuzumab-Emtansine (T-DM1) Resistance Development.

Miwa Fujihara et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.